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Abstract
As part of the decision-making process in cancer therapy selection, oncologists
stratify patients into broad clinical groups. At present, the major indicator for strat-
ification is the site of origin of the primary tumor. However, with the widespread
adoption of next generation sequencing technologies, our reference for stratification
is becoming more complex as we are beginning to understand how each tumor is
unique on the genetic level [1]. The outcome of this is an approach dubbed preci-
sion oncology, which involves the process of identifying genomic features driving
an individual tumor and designing a personalized therapeutic strategy in response
[2]. This presents a classification problem that is well suited to supervised machine
learning algorithms, although due to the high complexity and dimensionality of
such genomic data, applying models directly on the raw data can be difficult [3].
Common methods for reducing the dimensionality include incorporation of domain
expertise to select features with a high likelihood of impact, for example driver
genes[4] or cell signaling pathways[5]. The problem with this approach is it does
not allow for discoveries of novel sources of signal within the data.
In this study, we present Flatsomatic - a Variational Auto Encoder (VAE) optimized
to compress somatic mutations that allow for unbiased data compression whilst
maintaining the signal. We compared two different neural network architectures
for the VAE: Multilayer Perceptron (MLP) and bidirectional LSTM. The somatic
profiles we used to train our models consisted of 8,062 Pan-Cancer patients from
The Cancer Genome Atlas[6] and 989 cell lines from the COSMIC cell line
project[7]. The profiles for each patient were represented by the genomic loci
where somatic mutations occurred and, to reduce sparsity, the locations with a
frequency <5 were removed. We enhanced the VAE performance by changing its
evidence lower bound, and devised an F1-score based loss showing that it helps
the VAE learn better than with binary cross-entropy. We also employed beta-VAE
to weight the variational regularisation term in the loss function and showed the
best performance through a preliminary function to increase the weight of the
regularisation term with each epoch. We assessed the reconstruction ability of the
VAE using the micro F1-score metric and showed that our best performing model
was a 2-layer deep MLP VAE. Our analysis also showed that the size of the latent
space did not have a significant effect on the VAE learning ability. We compared
the Flatsomatic embeddings created to a lower dimension version of the data from
principal component analysis, showing superior performance of Flatsomatic, and
performed K-means clustering on both datasets to draw comparisons to known
cancer types of each profile. Finally, we present results that confirm that the
Flatsomatic representations of 64 dimensions maintain the same predictive power
as the original 8,298 dimensions vector, through prediction of drug response.
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Our work shows a great potential for the use of VAEs in creating lower dimension
representations of somatic mutation profiles. We believe that work such as this is
a highly important step in the use of somatic mutation data for machine learning
applications, and we hope this will help future researchers in bringing data-driven
models into the field of precision oncology.
1 Introduction
Analysis of somatic mutation profiles from cancer patients is essential in the development of cancer
research. However, the low frequency of most mutations and the varying rates of mutations across
patients makes the data noisy, sparse and extremely high dimensional. Such data is challenging to
statistically analyze as well as difficult to use in classification problems, for clustering, visualisation
or for learning useful information. Thus, the creation of low dimensional representations of somatic
mutation profiles that hold useful information about the DNA of cancer cells will facilitate the use of
such data in applications that will progress precision medicine. In this paper, variational autoencoders
(VAEs) [8] were used to create latent representations of somatic profiles.
2 Methods
The process of building the VAEs to compress somatic profiles was comprised of exploring different
neural network architectures and optimizing them to enhance their performance. Several changes
to the loss function of the VAE were explored [9] in order to learn more useful representations. All
models were implemented using Keras library [10] with TensorFlow backend.
The somatic profiles used to train our models were comprised of 8062 Pan-Cancer patients from The
Cancer Genome Atlas (TCGA)[11], and 989 cell lines from the COSMIC cell line project (CCLP).
The profiles for each patient are represented by the positions in the genome where the samples
have a somatic mutation. To pre-process the data, binary vectors of equal lengths were created for
each patient with ones marking the presence of a somatic mutation in a particular somatic mutation
location. To reduce the sparsity, the mutation locations with a frequency of less than 5 were removed.
2.1 Multi Layer Perceptron based models
The first architecture explored was a feed-forward network also known as multilayer perceptron
(MLP). A two-layer deep network in the encoder/decoder of the VAE were built with a batch
normalization [12] layer after each layer. Different combinations of the number of units in each layer
were attempted and the effect of changing the size of the latent space was studied. A leaky ReLU [13]
activation was used in the encoder layers, and a regular ReLU was used in the decoder layers except
for the final layer in the decoder which employed a sigmoid function. A dropout layer was added
after the first layer in the encoder/decoder, and L1 regularization was used with each dense layer. We
optimized with RMSprop, and the models were trained with a batch size of 128 for 100 epochs.
Figure 1: General architecture of MLP-VAE. The orange layers are the input and output data. The
light blue trapezoids represent the encoder and decoder layers with hidden layers. The green part in
the middle represents the latent space where the parameters outputted from the encoder are used to
sample z and create the embeddings. The embeddings are then inputted into the decoder to reconstruct
the data.
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2.2 Bi-directional LSTM
The second architecture attempted was a bidirectional LSTM [14] in the hopes that it would reduce
the significance of the order of mutations, especially those that are close to the end of the input
sequence. Although the order of mutations in a somatic profile are not important, we expect the
occurrence of certain mutations or a group of mutations together to hold important information, as a
result this architecture was deemed the most suitable to learn deeper patterns in the data. The number
of units in the LSTM was explored (1024, 512, 256, or 128) as well as the size of the latent space
(128, 64, 32, or 8).
Figure 2: Illustration of layout of bidirectional LSTM VAE built in this paper. The orange layers are
the input and output. The blue squares represent the reading of sequences in the bidirectional LSTM
layer. Both readings are then merged with a certain merge mode (summation or concatenation). The
parameters are then estimated from the output of the bidirectional LSTM layer, to create the latent
vector which is light green in the figure. The decoder consists of another bidirectional LSTM and it is
followed by a dense layer which is the same size as the original data.
2.3 Changes in Loss Function of VAE
The loss function of the VAE is comprised of a reconstruction loss and a variational regularization
term. The loss function is essential to help the decoder reconstruct a version of the data from the
embeddings as close as possible to the input data. Binary cross-entropy is usually used as the
reconstruction loss, however, we devised an F1-score based loss function to use as the reconstruction
loss and compared its performance to binary cross-entropy.
L = Ez∼q[log p(x | z)]−DKL(q(z | x) || p(z))
Figure 3: Comparison of F1-loss (red) and Cross-entropy (blue) during training.
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Recent studies [15] have been emphasizing the importance of the regularization term in the loss
function and the role it plays in creating useful latent representations. We have explored beta-VAE
[16], and different ways of introducing it.
2.4 Assessment of Representation
To assess the representation created by the VAE, 2-dimensional embeddings were created by the
best VAE and compared to a lower dimension version of the data created using principal component
analysis (PCA) [17]. Kmeans clustering was applied to both low-dimensional versions, and its results
were compared to the known cancer types of each profile using Normalized Mututal Information
(NMI) as a measure. The number of clusters created was 32 since there are 32 different cancer types.
The embeddings were also used in a given classification task and their performance was compared to
results when the raw data was used in the same task.
3 Results
To assess the reconstruction ability of the VAE, we performed a 80/20 % training/validation split, and
used the micro F1 score. The MLP-VAE currently has a better performance than the bidirectional
LSTM VAE, however, the preliminary results obtained by the bidirectional LSTM are promising and
under investigation for future work.
The test F1-Score after a 5-fold cross-validation obtained with the MLP-VAE is 20.4% and 17.1%
with the Bi-LSTM. Our analysis has shown that the size of the latent space does not play a big role in
the reconstruction ability of the VAE as long it is above 8. Table 1 shows the validation F1 after a
5-fold cross-validation, found with different latent space sizes.
Table 1: Effect of Latent Space Size on VAE reconstruction
Latent Space Size 2 8 32 64 128 265 512
Validation F1 Score % 15.68 20.55 20.88 20.41 20.50 20.18 20.21
We found that the use of the F1-score based loss helps the VAE reconstruct this form of data much
better than the binary cross-entropy loss. To assess this, we measure the cosine similarity. Figure
4 shows the performance of the VAE while training with the two losses. We have also found that
introducing the regularization term using a warm-up function and increasing its weight with each
epoch gives the best performance.
Figure 4: Comparison of F1-loss (left) and Cross-entropy (right) during training.
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3.1 Visualization
After performing Kmeans with 32 clusters on the embeddings from the best VAE and the lower
dimension of the data created by PCA, plots with reference to the clusters were created, and they can
be seen in Figure 2. The NMI for the clusters created in the VAE embeddings was 21%, and for the
version created by PCA it was 11% showing that the VAE embeddings are a better representation.
We also note here that the data is binary, making it inherently hard to represent with PCA.
Figure 5: Comparison of projections from PCA (left) and Flatsomatic (right) for visualization.
4 Current Application & Conclusion
We have used Flatsomatic in a semi-supervised setting to predict drug response from the GDSC [18]
dataset. We show (Table 2) that the performances are similar to the raw data. The advantage of
working with smaller spaces is that it enables the use of other relevant features, for example clinical
features, or additional abstract representations of further multi-omic profiles, all of which should be
explored further.
The work done in this paper has shown that there is a great potential for the use of VAEs in creating
utilizable lower dimension representations of somatic profiles. The VAE embeddings performed
better than PCA for a clustering task, and performed equally well to the raw high dimensional data
for a classification task.
Table 2: Predicting drug response with somatic profile
Data source Dimensionality Precision Recall F1-score
Mutations Counts 8298 0.732 0.614 0.667
Flatsomatic embeddings 64 0.721 0.621 0.667
Additional areas that would be suitable for further exploration would include the building and
optimizing of other neural network architectures, in addition to applying the FlatSomatic embeddings
to a semi-supervised task to increase classification performance.
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